Dermapharm Holding SE
OTC:DMPHF

Watchlist Manager
Dermapharm Holding SE Logo
Dermapharm Holding SE
OTC:DMPHF
Watchlist
Price: 39.56 USD
Market Cap: 2.1B USD

Net Margin
Dermapharm Holding SE

10%
Current
10%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
10%
=
Net Income
116m
/
Revenue
1.2B

Net Margin Across Competitors

No Stocks Found

Dermapharm Holding SE
Glance View

Market Cap
2.1B USD
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Dermapharm Holding SE stands as a noteworthy player, crafting a narrative of strategic growth and innovation. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm presents itself as a vertically integrated pharmaceutical company whose operations stretch from development and production to marketing and distribution. This integration allows them to maintain control over their value chain, ensuring efficiency and quality across diverse product lines. Dermapharm's portfolio spans over 900 active pharmaceutical ingredients, health products, and medical devices, fortified through keenly orchestrated acquisitions that enhance their market presence and product offerings. Such strategic steps enable Dermapharm to leverage established brands while venturing into new sectors, reinforcing its reputation as a dynamic force in the pharmaceutical landscape. Dermapharm primarily generates revenue by capitalizing on dermatological products, allergy treatments, systemic corticosteroids, and vitamin supplements. By addressing a broad spectrum of chronic and everyday health conditions, they serve both niche and mass-market demands across Europe. Dermapharm’s distinctive approach combines robust in-house research and development with targeted acquisitions, such as their acquisition of the Dr. Loges-Schuten pharmaceutical company, broadening their reach into phyto-pharmaceuticals and other sectors. Additionally, Dermapharm collaborates with partners to penetrate new geographical markets, thereby diversifying their revenue streams. Such initiatives underscore the company's agility and strategic foresight, ensuring sustained growth in a competitive industry.

DMPHF Intrinsic Value
52.11 USD
Undervaluation 24%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
10%
=
Net Income
116m
/
Revenue
1.2B
What is the Net Margin of Dermapharm Holding SE?

Based on Dermapharm Holding SE's most recent financial statements, the company has Net Margin of 10%.

Back to Top